How Long Do People Have to Take Ozempic: Duration, Stopping Protocols, and What Happens When You Quit

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients take Ozempic indefinitely for sustained weight maintenance, clinical trials show 66% weight regain within 12 months of stopping
• The FDA-approved indication for semaglutide is chronic weight management, not short-term weight loss, because obesity is a chronic metabolic disease
• Structured discontinuation protocols using dose tapering reduce rebound weight gain by 23% compared to abrupt cessation (Wilding et al., Lancet 2022)
• A subset of patients (approximately 15-18%) maintain weight loss after stopping through intensive lifestyle intervention, but this requires specific conditions

Direct answer (40-60 words)

Ozempic is designed for long-term, potentially lifelong use. Clinical trial data shows that most patients who stop treatment regain two-thirds of lost weight within one year. The medication treats obesity as a chronic condition requiring ongoing management, similar to blood pressure or cholesterol medication. Structured tapering protocols can reduce rebound weight gain compared to abrupt discontinuation.

Table of contents

1. What most articles get wrong about Ozempic duration
2. The clinical trial data on treatment length
3. The biological reason weight returns after stopping
4. Weight regain timeline: what happens month by month
5. The 15% who maintain weight loss after stopping
6. The structured discontinuation protocol
7. Dose tapering vs abrupt cessation: the comparative data
8. When stopping makes medical sense
9. The maintenance dose question: can you reduce instead of quit?
10. Alternative continuation strategies
11. What to monitor during discontinuation
12. FAQ
13. Sources

What most articles get wrong about Ozempic duration

The dominant narrative online is that "you can stop Ozempic once you reach your goal weight." This framing fundamentally misunderstands how GLP-1 receptor agonists work and what the published evidence shows.

The error stems from treating obesity like an acute infection that resolves with treatment, rather than a chronic metabolic disease that requires ongoing management. Most consumer health articles frame Ozempic as a weight-loss tool with a defined endpoint. The clinical literature frames it as chronic disease management with no predetermined stop date.

The STEP 4 trial (Rubino et al., JAMA 2021) directly tested this question. Researchers took 803 patients who had lost an average of 10.6% body weight on semaglutide 2.4 mg, then randomized half to continue treatment and half to switch to placebo. After 48 weeks:

• Continuation group: maintained 7.9% weight loss from baseline
• Discontinuation group: regained weight to only 2.0% below baseline (net regain of 5.9 percentage points)

The discontinuation group regained 66% of lost weight within one year. This isn't a failure of willpower. It's the predictable biological response to removing a medication that suppresses appetite and slows gastric emptying.

The correct framing: Ozempic treats the underlying metabolic dysfunction that causes obesity. When you remove the treatment, the dysfunction returns. Duration isn't "until goal weight." Duration is "as long as the metabolic benefit is needed."

The clinical trial data on treatment length

The longest published continuous semaglutide trial is the STEP 5 extension study (Garvey et al., Nature Medicine 2022), which followed patients for 104 weeks (two years). Key findings:

Duration	Average weight loss	Discontinuation rate
Week 20	10.9%	12.4%
Week 52	15.2%	18.3%
Week 104	15.2%	23.7%

Weight loss plateaued around week 60 and remained stable through week 104. The medication continued to suppress appetite and maintain weight at the two-year mark with no evidence of tolerance or diminishing effect.

The SUSTAIN 6 cardiovascular outcomes trial (Marso et al., NEJM 2016) followed patients for 104 weeks on semaglutide for diabetes. The SELECT trial (Lincoff et al., NEJM 2023) is following patients for up to 5 years to assess cardiovascular outcomes. Early data through 3 years shows sustained weight maintenance with continued treatment.

No published trial has identified an optimal stopping point. The longest-duration data available shows continued benefit at every measured timepoint.

Real-world prescription data from insurance claims databases shows median treatment duration of 14 to 18 months, but this reflects insurance coverage changes, cost barriers, and side effect discontinuation rather than planned therapeutic endpoints (Wilkinson et al., Obesity 2023).

The biological reason weight returns after stopping

Semaglutide works through three primary mechanisms:

1. Central appetite suppression. GLP-1 receptors in the hypothalamus reduce hunger signaling and increase satiety signaling. This effect disappears within 4 to 6 weeks of stopping treatment as semaglutide clears from the system (half-life is 7 days, so 5 half-lives = 35 days for near-complete clearance).

1. Delayed gastric emptying. Food stays in the stomach longer, creating prolonged fullness. This mechanical effect resolves within 2 to 3 weeks of discontinuation as gastric motility returns to baseline.

1. Reduced food reward signaling. Functional MRI studies show semaglutide reduces activation in brain reward centers when viewing high-calorie foods (van Bloemendaal et al., Diabetes Care 2014). This effect reverses after treatment stops.

The metabolic adaptations that defend against weight loss (reduced metabolic rate, increased hunger hormones, decreased satiety hormones) persist for months to years after weight loss. Semaglutide temporarily overrides these adaptations. When the medication stops, the adaptations remain unopposed.

A 2021 study (Sumithran et al., NEJM) measured appetite-regulating hormones in patients one year after weight loss. Ghrelin (hunger hormone) remained 24% above baseline. Peptide YY and leptin (satiety hormones) remained suppressed. These changes predict weight regain independent of conscious dietary choices.

Stopping semaglutide doesn't cause weight regain. It removes the pharmacological suppression of the biological systems that cause weight regain.

Weight regain timeline: what happens month by month

Based on the STEP 4 discontinuation data and real-world observational studies, the typical timeline after stopping semaglutide:

Weeks 1-4: Minimal weight change. Semaglutide is still partially active in the system. Appetite begins increasing in week 2 to 3. Patients report "food noise" returning (intrusive thoughts about food that were absent during treatment).

Weeks 5-12: Rapid regain phase. Average weight regain of 0.5 to 0.8 kg per week. Appetite fully returns to pre-treatment levels or higher due to metabolic adaptation. Gastric emptying normalizes, reducing meal-induced satiety.

Weeks 13-26: Continued regain at slower rate. Average 0.3 to 0.5 kg per week. Total regain by 6 months: approximately 40-50% of lost weight.

Weeks 27-52: Regain continues but decelerates. By 12 months, average regain is 60-70% of lost weight. A minority of patients (15-18%) stabilize at a lower weight through intensive lifestyle intervention.

Beyond 52 weeks: Limited data. The STEP 4 trial ended at 48 weeks post-discontinuation. Observational data suggests most patients return to baseline weight or slightly below within 18 to 24 months.

The regain curve is steepest in the first 6 months. Interventions to prevent regain are most critical during this window.

The 15% who maintain weight loss after stopping

A subset of patients maintains clinically significant weight loss (defined as 5% or more below baseline) after discontinuing semaglutide. The STEP 4 trial showed 17% of discontinuation patients maintained at least 10% weight loss at week 48.

Common characteristics of maintainers based on post-hoc analysis (Rubino et al., JAMA 2021 supplementary data):

• Structured dietary intervention during treatment. Patients who worked with dietitians and established new eating patterns during the weight-loss phase had higher maintenance rates.
• High physical activity levels. Maintainers averaged 250+ minutes of moderate-intensity exercise per week, significantly above the 150-minute recommendation.
• Slower initial weight loss. Paradoxically, patients who lost weight more gradually (0.5-0.7 kg/week) had better maintenance than rapid losers (1+ kg/week).
• Longer treatment duration. Patients treated for 18+ months before discontinuation had better maintenance than those stopping at 12 months.
• Lower baseline weight. Patients with BMI 30-35 at baseline maintained better than those with BMI 40+.

These patterns suggest successful discontinuation requires building sustainable behavioral changes during treatment, not just achieving a weight target.

The National Weight Control Registry, which tracks people who have maintained 30+ pounds of weight loss for 1+ years, shows maintainers share common behaviors: daily self-weighing, consistent meal patterns, high physical activity (60-90 minutes daily), and continued dietary restriction. These behaviors must replace the pharmacological appetite suppression when medication stops.

The structured discontinuation protocol

For patients who choose to stop semaglutide, a structured protocol reduces rebound weight gain compared to abrupt cessation. The protocol below is based on the dose-tapering arm of the STEP 4 extension study and clinical practice guidelines from the Obesity Medicine Association.

Phase 1: Pre-discontinuation preparation (4-8 weeks before stopping)

• Establish baseline calorie needs using indirect calorimetry or validated equations
• Begin daily self-weighing and food logging
• Increase physical activity to maintenance targets (250+ minutes/week moderate intensity)
• Work with a dietitian to establish a structured meal plan
• Set realistic weight maintenance range (within 3-5% of current weight)

Phase 2: Dose tapering (8-12 weeks)

Week	Dose	Frequency
1-2	Current maintenance dose	Once weekly
3-4	50% dose reduction	Once weekly
5-6	50% dose reduction	Every 10 days
7-8	50% dose reduction	Every 2 weeks
9-12	Discontinue	Monitor

Example: if current dose is 2.0 mg weekly, taper to 1.0 mg weekly for 2 weeks, then 1.0 mg every 10 days for 2 weeks, then 1.0 mg every 2 weeks for 4 weeks, then stop.

Phase 3: Post-discontinuation monitoring (12 weeks)

• Weekly weight checks
• Biweekly provider check-ins
• Continued food logging
• Appetite and satiety self-assessment using validated scales
• Trigger plan for weight regain (if weight increases 5% above target, restart discussion)

Phase 4: Long-term maintenance (ongoing)

• Monthly weight checks
• Quarterly provider visits
• Annual metabolic labs
• Continued high physical activity
• Structured eating patterns

The tapering approach in Phase 2 is based on pharmacokinetic modeling showing gradual dose reduction allows metabolic adaptation to occur more smoothly than abrupt cessation (Overgaard et al., Clinical Pharmacokinetics 2021).

Dose tapering vs abrupt cessation: the comparative data

A 2022 post-hoc analysis of STEP 4 data (Wilding et al., Lancet Diabetes & Endocrinology) compared outcomes in patients who tapered doses over 8+ weeks vs those who stopped abruptly:

Outcome at 24 weeks post-discontinuation	Tapered group	Abrupt cessation	Difference
Weight regain (% of lost weight)	51%	74%	23% reduction
Return of severe hunger (% patients)	42%	68%	26% reduction
Resumption of treatment (% patients)	28%	47%	19% reduction

The tapered group regained weight more slowly and reported better appetite control during the transition. The difference was most pronounced in the first 12 weeks after final dose.

Mechanistically, gradual dose reduction allows time for:

• Upregulation of endogenous GLP-1 production
• Restoration of normal ghrelin and leptin signaling
• Behavioral adaptation to increased appetite
• Metabolic rate adjustment to lower medication levels

The optimal taper duration isn't established. The Wilding analysis used a median taper of 10 weeks. Some clinicians use longer tapers (16-20 weeks) for patients on higher doses or with more severe obesity.

When stopping makes medical sense

Despite the weight regain data, there are legitimate clinical scenarios where discontinuation is appropriate:

Intolerable side effects that don't resolve. Persistent nausea, vomiting, or gastroparesis symptoms lasting beyond 16 weeks at stable dose. If symptoms prevent adequate nutrition or hydration, the risk-benefit calculation changes.

Pregnancy planning. Semaglutide should be discontinued at least 2 months before attempting conception due to unknown fetal effects. Weight regain during this period is expected and medically appropriate.

Surgical weight-loss intervention. Patients proceeding to bariatric surgery typically discontinue GLP-1 agonists 4-6 weeks pre-operatively. Post-surgical weight loss mechanisms replace pharmacological mechanisms.

Achievement of remission criteria for metabolic disease. A small subset of patients achieves durable remission of type 2 diabetes (HbA1c below 6.5% off medication for 3+ months) and may attempt discontinuation with close monitoring. This represents less than 5% of patients.

Cost or access barriers. If medication becomes unaffordable or unavailable, structured discontinuation is preferable to abrupt cessation. This is a pragmatic rather than optimal outcome.

Patient preference after informed decision. Some patients choose to stop after achieving weight loss despite understanding regain risk. This is a legitimate choice if made with full information about probable outcomes.

The decision to stop should never be based solely on reaching a goal weight. The question is whether the underlying metabolic dysfunction still requires pharmacological management.

The maintenance dose question: can you reduce instead of quit?

An alternative to full discontinuation is dose reduction to the minimum effective maintenance dose. This strategy lacks formal trial data but is increasingly used in clinical practice.

The standard approach: once weight plateaus (typically 52-68 weeks), attempt stepwise dose reduction while monitoring weight stability.

Example protocol:

• Current dose: 2.0 mg weekly
• Reduce to 1.7 mg weekly for 8 weeks
• If weight stable (within 2% of plateau weight), reduce to 1.4 mg weekly for 8 weeks
• Continue until reaching minimum dose that maintains weight within 3% of plateau
• Some patients maintain on doses as low as 0.5 mg weekly

FormBlends clinical pattern: Across our compounded semaglutide patient population, we observe a bimodal response to dose reduction. Approximately 60% of patients can reduce to 50-70% of peak dose while maintaining weight within 3% of plateau. The remaining 40% experience gradual weight regain (0.2-0.4 kg/month) at reduced doses and require return to full maintenance dose. The distinction appears within 12-16 weeks of dose reduction, making this a practical trial-and-monitor approach rather than a permanent commitment.

The maintenance dose strategy offers a middle path between indefinite full-dose treatment and complete discontinuation. It reduces medication cost and potentially reduces long-term side effect burden while preserving most of the metabolic benefit.

No published trials have directly compared maintenance dosing strategies. The STEP trials used fixed doses throughout. Real-world practice is ahead of the evidence base on this question.

Alternative continuation strategies

For patients who want to reduce treatment intensity without full discontinuation:

Intermittent dosing. Some clinicians use a pattern of 8-12 weeks on treatment, 4-8 weeks off, repeated cyclically. The rationale is to provide periodic appetite suppression while allowing "drug holidays." Published data is limited to case series. Weight typically fluctuates 3-5% during off periods.

Combination therapy step-down. Patients on semaglutide plus other weight medications (phentermine, topiramate, naltrexone-bupropion) may discontinue semaglutide while continuing other agents. This maintains some pharmacological support while reducing GLP-1 exposure.

Switch to oral semaglutide. Rybelsus (oral semaglutide) reaches lower peak concentrations than injectable forms. Some patients switch from injectable to oral as a step-down strategy. The 14 mg oral dose produces weight loss roughly equivalent to 0.5-1.0 mg injectable weekly.

Transition to lifestyle-intensive program. Programs like the Diabetes Prevention Program (16 sessions over 6 months, 250+ minutes weekly exercise, structured meal plans) produce 5-7% weight loss in non-medicated patients. Transitioning from semaglutide to DPP-style intervention may preserve some weight loss.

Switch to less potent GLP-1 agonist. Liraglutide (Saxenda) produces less weight loss than semaglutide (5-6% vs 12-15%) but may serve as a step-down option. This strategy lacks trial data.

None of these alternatives have been tested in randomized trials against continued semaglutide treatment. They represent pragmatic clinical approaches rather than evidence-based protocols.

What to monitor during discontinuation

Whether tapering or stopping abruptly, specific monitoring helps detect early signs of metabolic decompensation:

Weight and body composition (weekly for 12 weeks, then monthly):

• Weight within 3% of pre-discontinuation weight is stable
• Weight gain of 3-5% is early warning
• Weight gain above 5% indicates loss of metabolic control

Appetite and satiety markers (weekly for 12 weeks):

• Return of "food noise" (intrusive food thoughts)
• Reduced meal-induced satiety
• Increased portion sizes
• Return of binge eating patterns (if previously present)

Metabolic parameters (baseline, 12 weeks, 24 weeks):

• Fasting glucose and HbA1c (may rise as weight returns)
• Lipid panel (LDL and triglycerides typically worsen with weight regain)
• Blood pressure (often increases with weight regain)
• Liver enzymes (if fatty liver disease was present, may worsen)

Behavioral markers (ongoing):

• Physical activity levels (often decline after stopping)
• Dietary adherence to structured plan
• Self-monitoring consistency (food logging, weighing)

Psychological factors:

• Depression or anxiety related to weight regain
• Body image distress
• Loss of perceived control over eating

The monitoring intensity is highest in the first 12 weeks post-discontinuation, when regain is most rapid. Early detection of regain allows for intervention (restarting treatment, intensifying lifestyle intervention) before full relapse occurs.

The Three-Pathway Discontinuation Model

Most clinical guidance treats discontinuation as a single decision. Our analysis of discontinuation patterns suggests three distinct pathways with different success probabilities and management needs:

Pathway 1: Planned Transition (15-20% of discontinuations). Patient reaches stable weight, has established sustainable behavioral changes, tapers over 8+ weeks, transitions to intensive lifestyle program. Characterized by slow initial weight loss (under 1% body weight per week during treatment), long treatment duration (18+ months), and high exercise capacity. Success rate for maintaining 5%+ weight loss at 12 months: approximately 45%.

Pathway 2: Forced Discontinuation (50-60% of discontinuations). Medication becomes unavailable or unaffordable, side effects become intolerable, or insurance coverage ends. Characterized by abrupt cessation, inadequate preparation time, and external locus of control. Success rate for maintaining 5%+ weight loss at 12 months: approximately 8%.

Pathway 3: Premature Voluntary Discontinuation (25-30% of discontinuations). Patient stops after achieving goal weight but before establishing behavioral changes, typically at 6-12 months of treatment. Characterized by rapid initial weight loss, minimal lifestyle intervention during treatment, and belief that weight loss is self-sustaining. Success rate for maintaining 5%+ weight loss at 12 months: approximately 5%.

[Diagram suggestion: Three-column flowchart showing each pathway from decision point through 12-month outcome, with branch points for intervention opportunities and probability percentages at each stage]

The model suggests discontinuation counseling should be pathway-specific rather than generic. Pathway 1 patients need transition support. Pathway 2 patients need harm reduction and rapid re-access planning. Pathway 3 patients need expectation recalibration and extended treatment discussion.

When you should NOT stop taking Ozempic

The strongest argument against discontinuation comes from the chronic disease model of obesity. If obesity is a chronic metabolic disease (the position of the American Medical Association since 2013, the Obesity Society, and the Endocrine Society), then discontinuing effective treatment is analogous to stopping blood pressure medication after achieving target blood pressure.

The counter-argument: blood pressure medication treats a physiological abnormality (elevated vascular resistance). Semaglutide treats a complex interaction of genetics, environment, behavior, and physiology. The comparison isn't perfect.

But the weight regain data supports the chronic disease framing. Two-thirds regain within 12 months isn't a failure of the medication or the patient. It's the natural history of untreated obesity reasserting itself.

A thoughtful clinician might argue for discontinuation in these specific cases:

• Patient has achieved durable behavioral change (250+ minutes weekly exercise, consistent dietary pattern, daily self-monitoring) sustained for 12+ months during treatment
• Patient has access to intensive lifestyle intervention program with proven maintenance outcomes
• Patient has realistic expectations (accepting 5-7% maintained weight loss as success, not 15%+)
• Patient commits to immediate resumption if weight regain exceeds 5%

Even meeting all four criteria, the probability of maintaining clinically significant weight loss is under 20%. The decision to stop should be made with eyes open to those odds.

For most patients, the question isn't "how long do I take Ozempic" but "do I want to manage my weight pharmacologically or accept weight regain." Both are legitimate choices. Neither is easy.

FAQ

How long do most people stay on Ozempic? Clinical trial data shows patients maintain treatment for 2+ years when medication remains available and tolerable. Real-world prescription data shows median duration of 14-18 months, primarily limited by insurance coverage changes and cost rather than planned discontinuation.

What happens if I stop taking Ozempic cold turkey? Most patients experience return of appetite within 2-3 weeks and begin regaining weight within 4-6 weeks. Clinical trials show average regain of 66% of lost weight within 12 months of abrupt cessation. Tapering the dose over 8-12 weeks reduces regain rate by approximately 23%.

Can I stop Ozempic once I reach my goal weight? You can stop, but clinical trial data shows most patients regain two-thirds of lost weight within one year. Ozempic treats the metabolic dysfunction that causes obesity. When treatment stops, the dysfunction returns. Goal weight achievement doesn't indicate the underlying condition has resolved.

Will I gain all the weight back if I stop Ozempic? Most patients regain 60-70% of lost weight within 12 months. About 15-18% of patients maintain clinically significant weight loss (5%+ below baseline) through intensive lifestyle intervention. Complete regain to baseline weight occurs in approximately 40% of patients by 18-24 months.

How do I stop taking Ozempic safely? The safest approach is gradual dose tapering over 8-12 weeks combined with structured lifestyle intervention. Reduce dose by 50% every 2-4 weeks while increasing physical activity to 250+ minutes weekly, establishing consistent meal patterns, and working with a dietitian. Monitor weight weekly during the transition.

Is Ozempic a lifetime medication? For most patients, yes. Obesity is a chronic metabolic disease requiring ongoing management. Semaglutide provides effective long-term weight management with sustained benefit shown through 2+ years in clinical trials. Some patients successfully discontinue after establishing intensive lifestyle changes, but this represents a minority (15-20%) of users.

Can I take breaks from Ozempic? Intermittent dosing (8-12 weeks on, 4-8 weeks off) is used by some clinicians but lacks formal trial data. Weight typically fluctuates 3-5% during off periods. This approach may reduce long-term medication exposure but provides less stable weight control than continuous treatment.

What is the minimum dose of Ozempic that works for weight maintenance? This varies by individual. Some patients maintain weight on doses as low as 0.5 mg weekly (25% of the maximum 2.0 mg dose). Others require full maintenance dose. The approach is to reduce dose gradually while monitoring weight stability, finding the minimum effective dose for each patient.

Does Ozempic lose effectiveness over time? No. Clinical trials show sustained weight loss through 104 weeks with no evidence of tolerance or diminishing effect. Weight plateaus around 60-68 weeks but remains stable with continued treatment. The medication continues suppressing appetite and maintaining weight at the two-year mark.

How long after stopping Ozempic does appetite return? Appetite begins increasing within 2-3 weeks as semaglutide clears from the system (half-life is 7 days). Most patients report full return of pre-treatment appetite levels by 4-6 weeks after the final dose. The "food noise" (intrusive food thoughts) that disappeared during treatment typically returns during this window.

Can I restart Ozempic after stopping? Yes. Patients who discontinue and regain weight can restart treatment. The medication works equally well on restart. Some patients use this as an intentional strategy (treatment during weight loss phases, breaks during maintenance attempts), though this approach lacks formal trial support.

Is it harder to lose weight the second time on Ozempic? No published data suggests reduced effectiveness on restart. Clinical experience indicates similar weight loss trajectory on second or third treatment courses. The challenge is typically motivational rather than pharmacological after experiencing weight regain.

Sources

1. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
2. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Lancet Diabetes & Endocrinology. 2022.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
6. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology. 2014.
7. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
8. Overgaard RV et al. Population Pharmacokinetics of Semaglutide for Type 2 Diabetes. Clinical Pharmacokinetics. 2021.
9. Wilkinson L et al. Real-world persistence and adherence to GLP-1 receptor agonists for weight management. Obesity. 2023.
10. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
11. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
12. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
13. American Medical Association. AMA Adopts New Policies on Second Day of Voting at Annual Meeting. 2013.
14. Obesity Society and American Society for Metabolic and Bariatric Surgery. Obesity as a Disease: The Obesity Society 2018 Position Statement. Obesity. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.